Bengal Physician Journal

Register      Login

VOLUME 10 , ISSUE 2 ( May-August, 2023 ) > List of Articles


Motor Neuron Disease: The Contribution of TAR-43 Gene in Amyotrophic Lateral Sclerosis

Gorky Guha

Keywords : Amyotrophic lateral sclerosis, Familial amyotrophic lateral sclerosis, Sporadic amyotrophic lateral sclerosis, TAR DNA-binding protein 43

Citation Information : Guha G. Motor Neuron Disease: The Contribution of TAR-43 Gene in Amyotrophic Lateral Sclerosis. Bengal Physician Journal 2023; 10 (2):50-54.

DOI: 10.5005/jp-journals-10070-8009

License: CC BY-NC 4.0

Published Online: 07-08-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Motor neuron diseases are a spectrum of neurodegenerative disorders, characterized by their physicochemical propinquity for the voluntary motor systems. The most notorious of these neurodegenerative disorders is amyotrophic lateral sclerosis (ALS), which is a multifocal disorder affecting both lower and upper motor neurons. Amyotrophic lateral sclerosis has been defined as a progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control. Transactive response element (TAR) DNA binding protein 43 (TDP-43) is an ribonucleic acid (RNA)/DNA binding protein contributing to RNA-related metabolism. Hyperphosphorylated and ubiquitinated TDP-43 deposits function as inclusion bodies in the brain and spinal cord which causes ALS. Majority of the ALS cases are sporadic amyotrophic lateral sclerosis's (SALS's) and 5–10% of cases are familial amyotrophic lateral sclerosis (FALS), where mutations of the TDP-43 DNA binding protein (TARDBP) gene occur and the rest (90–95%) are due to mutations in other genes like C9ORF72, SOD1, etc. Whether the ALS is familial or sporadic it has been seen that there is a significant contribution of TDP43 protein in the ALS pathology. Thus, the modality of TDP43-based proteinopathies and its involvement in ALS has been the focal point in the study of ALS-mediated neurodegeneration.

  1. Xu L, Liu T, Liu L, et al. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: A systematic review and meta-analysis. Journal of neurology 2020;267(4):944–953. DOI: 10.1007/s00415-019-09652-y.
  2. Mancuso R, Navarro X. Amyotrophic lateral sclerosis: Current perspectives from basic research to the clinic. Prog Neurobiol 2015; 133:1–26. DOI: 10.1016/j.pneurobio.2015.07.004.
  3. François-Moutal L, Perez-Miller S, Scott DD, et al. Structural insights into TDP-43 and effects of post-translational modifications. Front Mol Neurosci 2019;12:301. DOI: 10.3389/fnmol.2019.00301.
  4. Maria Johanna de Boer E, K OrieV, Williams T, et al. TDP-43 proteinopathies: A new wave of neurodegenerative diseases. J Neurol Neurosurg Psychiatry 2020;92(1):86–95. DOI: 10.1136/jnnp-2020-322983.
  5. Peng AYT, Agrawal I, Ho YW, et al. Loss of TDP-43 in astrocytes leads to motor deficits by triggering A1-like reactive phenotype and triglial dysfunction. Proc Natl Acad Sci U S A 2020;117(46):29101–29112. DOI: 10.1073/pnas.2007806117.
  6. Riku Y, Seilhean D, Duyckaerts C, et al. Pathway from TDP-43-related pathology to neuronal dysfunction in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Int J Mol Sci 2021;22(8):3843. DOI: 10.3390/ijms22083843.
  7. Prasad A, Bharathi V, Sivalingam V, et al. Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis. Front Mol Neurosci 2019;12:25. DOI: 10.3389/fnmol.2019.00025.
  8. Egawa N, Kitaoka S, Tsukita K, et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med 2012;4(145):145ra104. DOI: 10.1126/scitranslmed.3004052.
  9. Buratti E. Functional Significance of TDP-43 Mutations in Disease. Adv Genet 2015;91:1–53. DOI: 10.1016/bs.adgen.2015.07.001.
  10. Oberstadt M, Stieler J, Simpong DL, et al. TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole. Sci Rep 2018;8(1):2248. DOI: 10.1038/s41598-018-20565-0.
  11. Crivello M, O'Riordan SL, Woods I, et al. Pleiotropic activity of systemically delivered angiogenin in the SOD1G93A mouse model. Neuropharmacology 2018;133:503–511. DOI: 10.1016/j.neuropharm.2018.02.022.
  12. Bissaro M, Moro S. Rethinking to riluzole mechanism of action: The molecular link among protein kinase CK1δ activity, TDP-43 phosphorylation, and amyotrophic lateral sclerosis pharmacological treatment. Neural Regen Res 2019;14(12):2083–2085. DOI: 10.4103/1673-5374.262578.
  13. Abhayraj S Joshi, Virender Singh, Avinash Gahane, et al. Biodegradable nanoparticles containing mechanism based peptide inhibitors reduce polyglutamine aggregation in cell models and alleviate motor symptoms in a drosophila model of huntington's disease. ACS Chem Neurosci 2019;10(3):1603–1614. DOI: 10.1021/acschemneuro.8b00545.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.